A cost-effectiveness approach to the qualification and acceptance of biomarkers.
about
Novel automated blood separations validate whole cell biomarkersGUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patientsBiomarker Validation for Aging: Lessons from mtDNA Heteroplasmy Analyses in Early Cancer Detection.Future prospects for biomarkers of alcohol consumption and alcohol-induced disordersDevelopment and use of integral assays in clinical trialsBridging the gap: moving predictive and prognostic assays from research to clinical useMolecular staging individualizing cancer management.Dissecting the human plasma proteome and inflammatory response biomarkers.GUCY2C molecular staging personalizes colorectal cancer patient managementWhere medicine, business, and public policy intersect.The role of clinical imaging in oncological drug development.Identification of discriminating biomarkers for human disease using integrative network biologyMolecular diagnostics. At the nexus of individualized medicine, health care delivery, and public policy.Systematic analytical validation of commercial kits for the determination of novel biomarkers for clinical drug development.Applications of 'decisionable' biomarkers in cardiovascular drug development.Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification.Promoter CpG island methylation markers in colorectal cancer: the road ahead.What evidence do we need for biomarker qualification?Three-year analysis of repeated laboratory tests for the markers total cholesterol, ferritin, vitamin D, vitamin B12 , and folate, in a large research and teaching hospital in Italy.Robust and tissue-independent gender-specific transcript biomarkers.
P2860
Q21560950-78FB4BAF-A260-4B83-A673-A54827DB220DQ24641833-63151FFB-C1BC-493B-91F2-49BD9A3F5C92Q33520448-E3262855-F782-4554-8586-86C3FC3D7232Q33976216-BD22932A-E73B-4F23-852C-1A95A24BFB1EQ35838558-639961C7-9EDF-4C11-9BEB-4EF98B604BABQ35838577-2B560E3C-95DB-4F20-8576-3A0C4B48E23DQ35854173-C3227638-F193-45E0-B559-F41C9404C724Q36110726-49C7734C-7365-4D60-84B0-7F16A03425C9Q36336227-711BBDDD-08E5-41B2-B91A-0E15C5CA9419Q36587516-616D0CDA-ECB4-4ADF-9066-DAE0CE31FF67Q37187098-3B0A6555-D799-413B-993A-C8CDF2BD5D20Q37357916-0F14D317-5E1E-4501-8DF9-E0596D2131C9Q37700478-BA735439-21A3-424E-9AB8-72959C0EA0F3Q37810247-E6596E41-5989-4006-A394-2D420737BF47Q37816414-8F7F463C-6D5D-46DD-BB3F-DDA364FB2E51Q37921314-F85CBDB4-34F7-4290-95E3-68EE2185C397Q37997086-0AB0FA78-66CC-4309-B2A6-66E7012BD4A3Q47571617-881A8236-D56A-4CC0-BFD6-3ECE3ED5EC0CQ47588001-FEB018D8-19AE-4B92-83FE-098DD2ADCFE0Q50856401-47A47702-0E0B-48F3-85E5-593898BB85BB
P2860
A cost-effectiveness approach to the qualification and acceptance of biomarkers.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
A cost-effectiveness approach to the qualification and acceptance of biomarkers.
@ast
A cost-effectiveness approach to the qualification and acceptance of biomarkers.
@en
type
label
A cost-effectiveness approach to the qualification and acceptance of biomarkers.
@ast
A cost-effectiveness approach to the qualification and acceptance of biomarkers.
@en
prefLabel
A cost-effectiveness approach to the qualification and acceptance of biomarkers.
@ast
A cost-effectiveness approach to the qualification and acceptance of biomarkers.
@en
P2093
P2860
P356
P1476
A cost-effectiveness approach to the qualification and acceptance of biomarkers.
@en
P2093
Christopher J Webster
David E Slavin
John A Wagner
Stephen A Williams
P2860
P2888
P304
P356
10.1038/NRD2174
P577
2006-11-01T00:00:00Z
P6179
1034368121